

SKIN CANCER (OTHER THAN MELANOMA)

## MY EXPERIENCE WITH INGENOL MEBUTATE IN CLINIC AND HYSTOLOGICAL ANATOMY

M Cordone (1)

Sanatorio Ipensa, Buenos Aires, La Plata, Argentina (1)

BACKGROUND: Four patients with acritic keratosis and field cancerization present themselves. The only treatment they underwent was ingenol mebutate. Before and after this treatment histopathological studies were carried out.

OBSERVATION: It was confirmed in a case in which the acritic keratosis had a severe dysplasia, and after the ingenol mebutate treatment, a histopatological study confirmed the dysplasia was slight. Moreover, all patients clinically improved and did not suffer from atrophy.

KEY MESSAGE: Ingenol mebutate topical treatment, clinical improvement, histological change with a decrease in the degree of dysplasia in acritic keratosis.





